Can GLP-1 Drugs Ease the Strain on a Failing Heart? New Pressure-Monitor Data Say Possibly Yes
Can GLP 1 Drugs Ease the Strain on a Failing Heart? New Pressure Monitor Data Say Possibly Yes Most of what we know about GLP 1 and dual GLP 1/GIP medications in heart failure…
Can GLP-1 Drugs Ease the Strain on a Failing Heart? New Pressure-Monitor Data Say Possibly Yes
Most of what we know about GLP-1 and dual GLP-1/GIP medications in heart failure comes from measuring outcomes we can see from the outside: hospitalizations, symptoms, quality-of-life scores. A small but intriguing new study, presented at the Heart Failure Society of America's Annual Scientific Meeting in Phoenix in October 2026, gives us a rare look inside the heart itself while patients are on these medications, and the findings help explain why the clinical benefits we have been observing may actually be happening.
Using an implanted sensor to watch the heart in real time
The study, led by Dr. Christopher Maulion at Yale, took advantage of a device many heart failure patients already have: a CardioMEMS sensor, a small implant placed in the pulmonary artery that continuously transmits pressure readings a care team can monitor remotely. These sensors exist specifically because pulmonary artery pressure tends to rise days to weeks before a patient feels sick enough to be hospitalized, giving doctors an early warning system.
Using Yale's CardioMEMS database, the researchers identified 60 patients, out of 506 implanted with the device, who had been started on either semaglutide (48 patients) or tirzepatide (12 patients) for at least six months. The average patient was 63.7 years old, and most were men.
What the pressure readings showed
Before starting these medications, patients' average pulmonary artery systolic pressure was 46 mmHg, already elevated. After three months on a GLP-1 or GLP-1/GIP medication, systolic pressure had fallen by nearly 3 mmHg, and by six months it had dropped by close to 3.75 mmHg, both statistically significant changes. Mean and diastolic pulmonary pressures fell as well. These are modest but real reductions in the pressure the right side of the heart has to work against, which is exactly the kind of change that tends to precede fewer hospital admissions.
And indeed, hospitalizations for heart failure dropped sharply, from an average of 1.2 admissions per year before starting the medication to 0.3 admissions per year afterward, comparing each patient's own year before and after treatment began.
An unexpected and genuinely interesting detail
One finding stood out as scientifically important rather than just reassuring: the researchers also tracked diuretic use, the water pills that help heart failure patients avoid fluid overload, and found that use of loop diuretics fell from 85% of patients to 67% by six months, without needing a higher dose in those who remained on them. In other words, these medications appeared to reduce the underlying congestion itself, not merely mask it by pushing patients toward more aggressive diuretic therapy.
Perhaps most interesting of all, the correlation between how much weight a patient lost and how much their pulmonary pressure improved was weak and not statistically significant. Patients lost an average of 4.4% of their body weight, yet the improvement in heart pressures did not track tightly with that number. This hints that these medications may be helping the heart through mechanisms beyond simple weight loss, potentially including direct effects on blood vessel function, inflammation, or fluid handling, something researchers are still working to understand.
What this means, and what it does not yet mean
I want to be careful here, because this is a small, retrospective, observational study of just 60 patients, presented as a conference abstract rather than published in a peer-reviewed journal. It cannot prove cause and effect, and the patients who were prescribed these medications may differ in other ways from those who were not. This is a hypothesis-generating signal, not a verdict.
That said, it adds a plausible physiological mechanism to a growing body of evidence that GLP-1-based therapies have real cardiovascular benefits in patients with heart failure, extending well beyond weight management alone. For patients with both obesity and heart failure, a combination increasingly common in my own clinic, this is one more reason these medications deserve serious discussion with your cardiology and obesity care teams together, rather than being viewed as a weight-loss drug that happens to also carry heart risk reduction as a side note.
Source: Maulion C, et al. Presented at the Heart Failure Society of America Annual Scientific Meeting, Phoenix, Arizona, October 9-12, 2026.
Related articles
How Do I Use Mounjaro? A Patient's Guide to Dosing, Injections, and Safety
Learn how to correctly use Mounjaro (tirzepatide), including injection sites, the step-up dosing schedule, handling missed doses, and storage guidelines.
A "Triple-Acting" Weight-Loss Combination: What Early Data on EloraTZP Show
Every few months lately, I find myself updating the mental list I keep of where obesity pharmacotherapy is heading next, and the data Eli Lilly presented at EASD 2026, the 62nd…
A Once-Monthly Weight-Loss Injection? What MariTide's Phase 2 Data Actually Show
One of the most common frustrations I hear from patients on weekly injectable weight loss medications is not about effectiveness — most patients are genuinely pleased with their…
Have questions about your own health?
Ask the AI Knowledge Center — trained on Professor Jamal's own publications and guidelines — or book a consultation in person.